Type 1 diabetes is one of the most common endocrine problems in childhood and adolescence and its incidence is increasing.
with currently available conventional insulin pump therapy, whereby insulin is delivered at pre-programmed rates and only intermittently adjusted. Closed-loop systems comprise three main components (see Figure 1 ): a CGM device, a control algorithm that determines the insulin delivery rate, and a portable electromechanical insulin pump.
For practical reasons, the subcutaneous approach for continuous glucose sensing and insulin delivery has become the preferred mode of operation. Other modes, such as the intravenous approach for glucose sensing and insulin delivery, may be of use for example in intensive care settings.
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Continuous Glucose Monitoring
CGM devices consist of a disposable sensor that is implanted into the subcutaneous tissue, a non-implanted transmitter that powers the sensor and transfers data wirelessly, and a hand-held receiver.
The sensors used in the commercially-available devices contain the enzyme glucose oxidase, which converts glucose into gluconic acid and hydrogen peroxide. 12 The resulting changes in electrical charge are proportional to the concentration of glucose. The signal is transmitted to the hand-held receiver, which converts the measured current into glucose values using a transformation algorithm using one or more reference glucose values obtained via finger-prick glucose testing. This process is commonly referred to as calibration. The receiver also acts as the user interface, with information on glucose data updated every one to 10 minutes, a graphical display of glucose levels for user-specified time periods and also glucose trend arrows and alarms alerting the user to impending hyper-or hypoglycemia. Information on hyper-and hypoglycemia is particularly useful as the direction of glucose drift will allow the user to take precautionary action before a significant event occurs. Receivers can be either standalone devices (such as Guardian RT, FreeStyle Navigator and Dexcom) or incorporated into insulin pumps (Medtronic Veo pump with MiniLink Sensor).
The landmark JDRF-funded CGM study 13 showed that in adults ≥25 
Control Algorithms
The role of the control algorithm is to translate, in realtime, the information it receives from the glucose monitor and to compute the amount of insulin to be delivered by the insulin pump. Only a brief description of control algorithms is provided here. A more detailed account can be found elsewhere. 31 There are two main categories of control algorithms, i.e the model predictive control (MPC) [32] [33] [34] and classic feedback control embodied in the proportional-integral derivative (PID)
controller. [35] [36] [37] [38] MPC is at the forefront of current research with contributions, for example, by Wang et al., 39 El-Khatib et al., 40 Lee et al., 41 and Hovorka et al. 32 The vital component of MPC is a model linking insulin information, such as subject's weight, 40 total daily insulin dose and preprogrammed basal rate. 42 These algorithms can adapt themselves to time-varying insulin needs in realtime based on sensor glucose levels. 40 However, most algorithms adopt a non-adaptive approach using offline initialization. Further research is needed to determine the optimum frequency of adaptation.
Clinical Studies of Closed-loop Insulin Delivery Systems

Suspended Insulin Delivery
The simplest form of a closed-loop system is to suspend insulin delivery when the patient reaches a hypoglycemic state. Introduced in 2009, the Medtronic Veo pump coupled with a CGM sensor suspends insulin delivery for up to two hours if hypoglycemia alarms are not acknowledged. The main objective of this approach is to reduce the severity and duration, but not the incidence, of hypoglycemia. Recent work by Dassau et al. 43 and Buckingham et al. 44 highlights the development and use of a more advanced approach combining five algorithms to predict and prevent hypoglycemia. During the latter study, 44 in the first 14 subjects hypoglycemia was induced by gradually increasing the basal insulin infusion rate without the use of pump 
Overnight Closed-loop Control
Sleep is a recognized risk factor for severe hypoglycemia due to absent warning symptoms and blunted sympatho-adrenal response. 47 Nocturnal hypoglycemia is therefore very common but often asymptomatic and undetected-an observation that has been confirmed by the use of CGM. 9 Furthermore, 75% of hypoglycemic seizures in children occur during sleep. 48 Severe nocturnal hypoglycemia may be implicated in dead-in-bed syndrome. 49, 50 Since overnight glucose control is not challenged by exercise or meals, overnight closed-loop control is a simpler but important step towards the goal of an artificial pancreas. closed-loop nights. Average overnight insulin delivery was similar during closed-loop and standard treatment. 42 The preliminary results in adults 51, 52 and pregnant women 53 are also promising.
Cross-over Studies
Day and Night Closed-loop Control
Providing closed-loop control during the daytime is more challenging due 
Cumulative probability of plasma glucose concentrations during closed-loop (CL) insulin delivery and continuous subcutaneous insulin infusion (CSII) obtained during overnight studies in Cambridge in children and adolescents. The vertical dashed lines denote the target glucose range (3.91-8.00mmol/l). The inset shows detail at low plasma glucose concentrations. The numbers in rows are the total percentage time for which plasma glucose was lower than, within, or higher than the target range from the start of CL control at 8 pm until 8 am the next day. Reproduced with permission. 42
closed-loop control during the post-prandial period. For example, in early closed-loop feasibility studies, post-prandial hyperglycemia resulted in insulin overdelivery leading to late post-prandial hypoglycemia requiring rescue carbohydrates. 54 One of the ways to minimize post-prandial hypoglycemia is to announce the meal. In a subsequent study conducted by the Yale group, the fully closed-loop approach without meal announcement was tested against the meal announcement approach accompanied with a small prandial insulin bolus 10-15 minutes before the meal. 55 This study was performed using Medtronics ePID system using a proportional integral derivative controller in 17 well-controlled adolescents over 34 hours of closed-loop control. The meal announcement approach tended to improve post-prandial glucose levels (peak 10.8±2.6 versus 12.5±2.8mmol/l) and mean glucose levels (7.5±2.5 versus 7.8±3.1mmol/l). 55 The overall night glucose levels and associated standard deviations were excellent (6.2±1.5mmol/l). In the last 24 hours of closed-loop control, three nocturnal hypoglycemic events (<3.3mmol/l) were observed. 55 In a further study using a and 70g of carbohydrates, 73% of the sensor values ranged between 3.9-10mmol/l, 27% were >10mmol/l, and none were <3.9mmol/l. 58 There were no symptomatic hypoglycemic events. Further studies are planned under daily life conditions.
Dual Hormone Closed-loop
It may be possible to improve the performance of closed-loop systems by the use of other hormones in addition to insulin. Damiano et al. 59 and
Ward et al. 60 have investigated the use of glucagon co-administration to reduce the risk for hypoglycemia. In the former study by Damiano et al.,
an MPC controller was used for insulin and a PID controller for glucagon administration. No hypoglycemia (<3.9mmol/l) was observed during 24
hours of fully closed-loop in 11 adults once an appropriate model of insulin absorption was used. 59 Insulin and glucagon delivery were dependent on blood glucose and further investigation evaluating the approach with sensor glucose values are warranted. In the study by Ward et al., 60 use of glucagon resulted in significantly less time spent in the hypoglycemic range (15±6 versus 40±10 minutes/day). In addition, use of glucagon in high-gain pulses were more effective than slow, prolonged infusion. This reduced the frequency of hypoglycemic events (1.0±0.6 versus 2.1±0.6 events/day) and the need for carbohydrate treatment (1.4±0.8 versus 4.0±1.4 treatments/day). 60 Further studies are under way to examine the effect of other hormones, such as pramlintide. The limitations of using a multihormone approach include the need for dual-chamber insulin pumps, the need for stable glucagon analogs, and the need for two delivery catheters.
Intraperitoneal Insulin Delivery
Reported benefits of intraperitoneal insulin delivery include fast insulin action and reduced variability of insulin absorption. Renard et al. 61, 62 have examined the feasibility and efficacy of intraperitoneal insulin delivery over two days in eight adults with an implanted insulin pump driven by subcutaneous glucose sensor using a PID algorithm (ePID Medtronic system) with pre-meal insulin dosing. Excluding two early post-prandial hours, the closed-loop system achieved a higher percentage of time in the 4.4-6.6mmol/l range (46±5 versus 29±7%) and lower mean blood glucose levels (6.9±0.8 versus 7.9± 1.6mmol/l). 61 Time spent with blood glucose <3.3mmol/l was low and similar for both closed-loop and conventional treatment.
Simulators
The development, evaluation, and testing of closed-loop systems is time-consuming and costly. Testing in a computer-based environment with a collection of virtual subjects may provide valuable information.
This idea was originally advocated by Chassin et al. 63 The Institute 
Challenges and the Way Forward
Despite the progress that has been made in closed-loop insulin delivery over the last decade, challenges remain. Accuracy and reliability of CGM is often considered a bottleneck and further improvements may facilitate the increased safety and efficacy of closed-loop performance. With current rapid-acting insulin analogs, a substantial delay exists between subcutaneous insulin delivery and the reduction in blood glucose. It may take 90-120 minutes to reach the maximum extent of blood glucose-lowering after administration of a subcutaneous bolus of a rapid-acting insulin analog. 18 This is often underappreciated.
In a fully closed-loop system without meal announcement, the controller depends on the rate of glucose increase for the delivery of an insulin bolus, with a risk for overaggressive insulin delivery during post-prandial peaks. In order to prevent hypoglycemia, high glucose levels have to be normalized slowly, even during closed-loop periods.
The means to account for insulin on-board during closed-loop control have been suggested as a safety feature. 69 So far, studies have used the slightly less ambitious semi-automated approach of meal announcement and use of a pre-meal bolus. Ultrafast-acting insulin analogs or other means to accelerate insulin absorption or, alternatively, reversibly and systematically slow down the absorption of subcutaneously administered insulin would provide the greatest additional benefit. They can facilitate greater physiological prandial glucose control and may allow safe and efficacious fully closed-loop control. Human hyaluronidase co-administration with insulin is promising. 70, 71 Similarly, VIAject insulin appears to be absorbed faster than existing rapid-acting analogs.
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Progress with Closed-loop Systems in Type 1 Diabetes
Local heating has been proposed to accelerate insulin absorption 73 as well as dermal insulin delivery. The pharmacokinetic and pharmacodynamic characteristics of rapid-acting insulin analogues vary between and within subjects. 74 An incorrect assumption about insulin pharmacokinetics may lead to insulin overdosing and late post-prandial hypoglycemia during closed-loop control. 59 Up to four-fold between-subject variability in lispro pharmacokinetics has been observed with occasionally as much as a 50% within-subject variability on repeated occasions. 60 A more modest 20-25% within-subject variability has been reported in healthy subjects under controlled conditions. 74 A further challenge to closed-loop systems is the within-subject variability of insulin needs. These include day-to-day but also to hour-to-hour 
Conclusions
The development of a safe and reliable automated closed-loop insulin delivery system has long been considered the holy grail of type 1 
